Important Notice for Pacira BioSciences Investors
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is reaching out to investors of Pacira BioSciences, Inc. (NASDAQ: PCRX). If you have experienced financial losses exceeding $100,000 due to your investment in this company, you may have the opportunity to file as a lead plaintiff in a class action lawsuit.
Understanding the Class Action Lawsuit
The deadline to apply for lead plaintiff status is approaching. As an investor who purchased shares between specific dates during the Class Period, you are encouraged to take immediate action. The firm emphasizes the importance of this lawsuit, which is currently pending in the United States District Court for the District of New Jersey.
Why This Lawsuit Matters
This class action lawsuit centers around allegations that Pacira and its executives failed to disclose crucial material information to shareholders. Such omissions can lead to significant financial losses for investors, making legal recourse essential.
For context, a significant event occurred on August 9, 2024, when Pacira disclosed unfavorable news regarding its Exparel product. This product generates about 80% of the company’s revenue. The news included the decision that its key patent was found invalid, which caused a dramatic fall in the stock price—over 47%—within a single day. Shareholders were understandably upset, as the value per share plummeted from $22.36 to a low of $11.70.
What Investors Can Do
Investors interested in understanding their rights should reach out to KSF Managing Partner Lewis Kahn at no cost. As part of the process, you will be able to discuss your legal options and how this case may impact your ability to recover losses incurred during the Class Period.
About Pacira BioSciences
Founded with a commitment to innovative products that improve patient care, Pacira BioSciences has positioned itself in the biopharmaceutical industry. The company focuses on multimodal pain management solutions, including Exparel and other products designed to assist healthcare professionals and patients alike.
Historically, Pacira has been at the forefront of providing non-opioid pain relief options, contributing significantly to patient recovery processes and addressing the nationwide opioid crisis.
Understanding the Legal Context
The case being referred to is documented as Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322. By participating as a lead plaintiff, individuals join in a collective effort to hold corporations accountable for transparency and integrity in their disclosures.
As this lawsuit unfolds, it is expected that Pacira will face scrutiny, and more information may arise about its operational practices and financial reporting. This is crucial for current and potential investors to monitor closely.
How Kahn Swick & Foti, LLC Can Assist
With a remarkable track record in securities litigation, Kahn Swick & Foti, LLC delivers legal expertise and advocacy for investors embroiled in corporate fraud. Their multi-faceted approach ensures that clients receive comprehensive support whether they are individual investors or institutions facing significant losses.
The firm operates across several states, actively seeking justice for clients subjected to securities fraud. Their commitment reflects a strong dedication to protecting investor rights.
Moving Forward
As an investor in Pacira BioSciences, it is imperative to stay informed about developments in the class action lawsuit. Early action can be pivotal for those wishing to recover losses, and KSF is available to guide you through the process and legal intricacies.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit accuses Pacira BioSciences of failing to disclose vital information that affected its stock price, particularly regarding its Exparel product's patent status.
When is the deadline to file for lead plaintiff?
The deadline to file a lead plaintiff application in the class action lawsuit is approaching.
How can I contact Kahn Swick & Foti, LLC?
You can contact KSF Managing Partner Lewis Kahn toll-free to discuss your case and rights without any obligation.
What happens if I join the lawsuit?
Joining the lawsuit as a lead plaintiff allows you to represent the interests of all impacted investors and potentially recover losses incurred due to the alleged securities violations.
What are the next steps if I am a shareholder?
Reach out to KSF to understand your legal options and make sure your voice is heard in this important case.
